Who are Lithium or Valproate with Aripiprazole's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lithium-or-valproate-with-aripiprazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Lithium or Valproate with Aripiprazole — Competitive Intelligence Brief

Lithium or Valproate with Aripiprazole (Lithium or Valproate with Aripiprazole) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atypical antipsychotic combined with mood stabilizers. Area: Psychiatry.

marketed Atypical antipsychotic combined with mood stabilizers Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); inositol monophosphatase, GSK-3 (lithium); histone deacetylase (valproate) Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

Lithium or Valproate with Aripiprazole (Lithium or Valproate with Aripiprazole) — Otsuka Pharmaceutical Development & Commercialization, Inc.. Aripiprazole acts as a dopamine D2/D3 receptor partial agonist and serotonin 5-HT1A partial agonist, while lithium and valproate modulate intracellular signaling and gene expression to enhance mood stabilization and reduce manic/depressive symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lithium or Valproate with Aripiprazole TARGET	Lithium or Valproate with Aripiprazole	Otsuka Pharmaceutical Development & Commercialization, Inc.	marketed	Atypical antipsychotic combined with mood stabilizers	Dopamine D2/D3 receptors, serotonin 5-HT1A receptor (aripiprazole); inositol monophosphatase, GSK-3 (lithium); histone deacetylase (valproate)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atypical antipsychotic combined with mood stabilizers class)

Otsuka Pharmaceutical Development & Commercialization, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lithium or Valproate with Aripiprazole — Competitive Intelligence Brief. https://druglandscape.com/ci/lithium-or-valproate-with-aripiprazole. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab